Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 385 of 5804
-
New pill could stop and treat dangerous swelling attacks
Disease control Recruiting nowThis is a Phase 3, multicenter, 3-part study, with 2 randomized, double-blind, placebo-controlled parts and an open-label extension part, to evaluate the efficacy and safety of orally administered deucrictibant XR tablet for prophylaxis, and deucrictibant IR capsule for on-demand…
Phase: PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Eye scans and voice tests may spot Parkinson's without needles
Diagnosis Not yet recruitingThis study will investigate new, non-invasive methods to help diagnose Parkinson's disease. Researchers will use advanced eye imaging (hyperspectral retinal photography and OCT), computerized memory and thinking tests, and voice analysis to identify patterns linked to Parkinson's…
Sponsor: Blekinge Institute of Technology • Aim: Diagnosis
Last updated Jun 27, 2026 07:53 UTC
-
New drug combo aims to shed pounds and control diabetes
Disease control Recruiting nowThe purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New shot could help heavy drinkers cut back
Disease control Recruiting nowThe purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with Alcohol Use Disorder (AUD) and hazardous alcohol use. Participation in this study will last approximately 56 weeks.
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New shot aims to stop bleeding in rare blood disorder
Disease control Recruiting nowThis is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)
Phase: PHASE3 • Sponsor: Vega Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New antifungal drug could shield liver transplant patients from deadly infections
Disease control ENROLLING_BY_INVITATIONThis is an interventional study to evaluate the efficacy of rezafungin, a new echinocandin, for the prevention of invasive fungal infections (IFIs) after liver transplantation. Patients who receive rezafungin will be compared to a similar group of patients who underwent liver tra…
Phase: PHASE3 • Sponsor: Fernanda P Silveira, MD, MS • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
AI vs. radiologist: 400,000 women join landmark breast cancer screening trial
Diagnosis Recruiting nowThe goal of this clinical trial is to compare patient-centered outcomes when screening digital breast tomosynthesis (DBT) exams are interpreted with versus without a leading FDA-cleared artificial intelligence (AI) decision-support tool in real-world U.S. settings and to assess p…
Phase: PHASE4 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 08:00 UTC
-
New drug aims to curb alcohol cravings in major trial
Disease control Recruiting nowThe purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with moderate-to-severe Alcohol Use Disorder (AUD). Participation in this study will last approximately 56 weeks.
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug cocktail aims to fight tough bile duct cancer
Disease control Not yet recruitingThis study is a randomized, controlled, open-label, single center clinical study. This study is designed to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Combined With GC versus Sintilimab Combined With GC as first-line therapy in advanced ICC.
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 26, 2026 12:36 UTC
-
Gene therapy for SMA tested in real-world settings of poorer nations
Disease control Recruiting nowThe study objective is to determine the real-world safety and effectiveness of Vesemnogene lantuparvovec for the treatment of SMA. The specific objectives are: * To determine clinical effectiveness of Vesemnogene lantuparvovec therapy for SMA as evaluated by developmental gross…
Phase: PHASE3 • Sponsor: Lantu Biopharma • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New cocktail aims to slow aggressive lung cancer
Disease control Recruiting nowThis is a Phase II, single-arm, single-center study evaluating Chidamide combined with a PD-L1 inhibitor, carboplatin, and etoposide as first-line therapy in extensive-stage small-cell lung cancer (ES-SCLC) patients. The primary objective is to assess Progression-Free Survival (P…
Phase: PHASE2 • Sponsor: China Medical University, China • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Triple threat: immunotherapy plus chemo and radiation takes on head and neck cancer
Disease control Recruiting nowHead and neck squamous cell carcinoma (HNSCC) is often diagnosed at a locally advanced stage, where cisplatin-based chemoradiotherapy is standard but still results in high recurrence rates. Immunotherapy is promising for HNSCC due to its high mutational burden, and adding PD-1 in…
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Engineered TB bacteria could offer new hope for bladder cancer patients
Disease control Recruiting nowThis is a phase 1/2, open-label, multicenter study of intravesical Recombinant Mycobacterium Bacillus Calmette-Guérin (BCG) in participants with Non-muscle invasive bladder cancer (NMIBC) who have not received Bacillus Calmette-Guérin and have histologically confirmed presence of…
Phase: PHASE1, PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Can a phone app break the silence on suicide? new study aims to find out.
Symptom relief Recruiting nowSuicide is one of the leading causes of death in Spain, representing a public health crisis that requires urgent and effective solutions. The stigma surrounding suicide prevents many at-risk individuals from seeking help, worsening the problem. Addressing this stigma is essential…
Phase: NA • Sponsor: University of Valencia • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Tailored swim lessons could save autistic children from drowning
Disease control CompletedAutistic children drown at one-hundred sixty times the rate of their neurotypical peers: a public health crisis that the adapted learning field has only addressed by demonstrating that standard swimming instruction sometimes works for autistic children. This study presents a thre…
Phase: NA • Sponsor: Genesis Indep Research • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New combo therapy targets liver metastases in rare eye cancer
Disease control Recruiting nowThis study is a multicenter, open label phase I/ II trial to assess the safety and clinical efficacy of tebentafusp-tebn in combination with liver-directed therapies in HLA-A\*0201 positive patients with metastatic uveal melanoma. In Part 1 of the study, the Prinicipal Investigat…
Phase: PHASE1, PHASE2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Can a traditional chinese herb tame stubborn rheumatoid arthritis?
Disease control Recruiting nowTo evaluate the efficacy and safety of Kunxian Capsule combined with Methotrexate and Tofacitinib in the treatment of difficult-to-treat rheumatoid arthritis through a multicenter, randomized, double-blind, placebo-controlled clinical trial, and to identify the therapeutic advant…
Phase: PHASE4 • Sponsor: Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug combo aims to tackle tough lymphoma cases
Disease control Not yet recruitingThis is a phase II study designed to evaluate the toxicity and efficacy of the combination of loncastuximab tesirine and epcoritamab in patients with relapsed/refractory aggressive B-cell lymphoma. Chimeric antigen receptor (CAR)-T cell naive patients who have failed first-line t…
Phase: PHASE2 • Sponsor: Universität Münster • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug combo aims to control Hard-to-Treat prostate cancer
Disease control Recruiting nowThis is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with progressive metastatic castrate resistant prostate cancer…
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for Tough-to-Treat blood cancers: NX-5948 trial opens
Disease control Recruiting nowThis is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibitor. The main purpose of this study is to t…
Phase: PHASE2 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC